ReviewGene therapy2005
Retroviral vector production in the National Gene Vector Laboratory at Indiana University.
Review in Gene therapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Lentiviral Vector Bioprocessing.Viruses · 2021Review
- Continuous production process of retroviral vector for adoptive T- cell therapy.Biochemical engineering journal · 2018Article
- Progress and challenges in viral vector manufacturing.Human molecular genetics · 2016Review
- Vector production in an academic environment: a tool to assess production costs.Human gene therapy methods · 2013Article
- Rapid titration of retroviral vectors using a β-lactamase protein fragment complementation assay.Gene therapy · 2013Article
- Scale-up and manufacturing of clinical-grade self-inactivating γ-retroviral vectors by transient transfection.Gene therapy · 2012Article
- Production of CGMP-Grade Lentiviral Vectors.BioProcess international · 2012Article
- Highly efficient concentration of lenti- and retroviral vector preparations by membrane adsorbers and ultrafiltration.BMC biotechnology · 2011Article
- Rapid production of clinical-grade gammaretroviral vectors in expanded surface roller bottles using a "modified" step-filtration process for clearance of packaging cells.Human gene therapy · 2011Article
- Suspension packaging cell lines for the simplified generation of T-cell receptor encoding retrovirus vector particles.Gene therapy · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The National Gene Vector Laboratory (NGVL) is a US National Institutes of Health initiative charged with providing clinical grade vectors for gene therapy trials. The program was started in 1995 and Indiana University has served as the production site for retroviral vectors and is also accepting applications for production of lentiviral vectors. The facility is designed to produce vectors for Phase I and Phase II clinical trials with the specific mandate to facilitate investigator-initiated research for academic institutions. To date, the facility has generated over 30 Master Cell Banks for gene therapy investigators throughout the United States. This required the facility to develop a system that can adapt to the varied needs of investigators, most of whom request different vector backbones, packaging cell lines, final product volumes, and media. In this review, we will illustrate some of the experiences of the Indiana University NGVL during the generation of retroviral vectors using murine-based packaging cell lines.
Indexed as
Identifiers
16231053What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.